Hemoglobin A1c and mortality in older adults with and without diabetes: Results from the national health and nutrition examination surveys (1988-2011)

Diabetes Care

Volumn 40, Issue 4, 2017, Pages 453-460

  Palta, Priya ^a,b   Huang, Elbert S ^c   Kalyani, Rita R ^d   Golden, Sherita H ^a,d   Yeh, Hsin Chieh ^a,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

AGED; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; REVIEW; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDY; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; NEOPLASMS; NUTRITION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MORTALITY; NEOPLASMS; NUTRITION SURVEYS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 85019607754     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dci16-0042     Document Type: Review

References (28)

1. Saydah S, TaoM, Imperatore G, Gregg E. GHb level and subsequent mortality among adults in the U.S. Diabetes Care 2009;32:1440-1446
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet 1998;352: 1558]. Lancet 1998;352:854-865
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet 1999;354: 602]. Lancet 1998;352:837-853
4. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
5. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
7. Hayward RA, Reaven PD, Emanuele NV; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:978
8. MillerME, Williamson JD, Gerstein HC, et al.; ACCORD Investigators. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care 2014;37:634-643
9. Colayco DC, Niu F, McCombs JS, Cheetham TC. A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study. Diabetes Care 2011;34:77-83
10. van Hateren KJ, Landman GW, Kleefstra N, et al. Glycaemic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20). Int J Clin Pract 2011;65:415-419
11. Chonchol M, Katz R, Fried LF, et al. Glycosylated hemoglobin and the risk of death and cardiovascular mortality in the elderly. Nutr Metab Cardiovasc Dis 2010;20:15-21
12. Tsigos C, Bitzur R, Kleinman Y, et al. Targets for body fat, blood pressure, lipids, and glucoselowering interventions in healthy older people. Diabetes Care 2013;36(Suppl. 2):S292-S300
13. Moreno G, MangioneCM, Kimbro L, Vaisberg E; American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of Older Adultswith DiabetesMellitus: 2013 update. J Am Geriatr Soc 2013;61:2020-2026
14. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care 2012;35: 2650-2664
15. Cahn A, Raz I, Kleinman Y, et al. Clinical assessment of individualized glycemic goals in patients with type 2 diabetes: formulation of an algorithm based on a survey among leading worldwide diabetologists. Diabetes Care 2015; 38:2293-2300
16. National Center for Health Statistics Office of Analysis and Epidemiology. NCHS 2011 Linked Mortality FilesMatchingMethodology, September 2013 [Internet]. Hyattsville, MD, National Center for Health Statistics. Available fromhttps://www.cdc.gov/nchs/data/datalinkage/2011-linked-mortality-file-matching-methodology.pdf. Accessed 22 January 2017
17. Carson AP, Fox CS, McGuire DK, et al. Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes. Circ Cardiovasc Qual Outcomes 2010;3:661-667
18. American Diabetes Association. Older adults. Sec. 10. In Standards of Medical Care in Diabetesd2016. Diabetes Care 2016;39 (Suppl. 1):S81-S85
19. Fabbian F, De Giorgi A, Monesi M, et al. Allcause mortality and estimated renal function in type 2 diabetes mellitus outpatients: Is there a relationship with the equation used? Diab Vasc Dis Res 2015;12:46-52
20. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the Diabetes and Aging Study. Diabetes Care 2011;34:1329-1336
21. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-489
22. Twito O, Ahron E, Jaffe A, et al. New-onset diabetes in elderly subjects: association between HbA1c levels, mortality, and coronary revascularization. Diabetes Care 2013;36:3425-3429
23. Riddle MC, Ambrosius WT, Brillon DJ, et al.; Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-causemortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33:983-990
24. Papademetriou V, Lovato L, Doumas M, et al.; ACCORD Study Group. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int 2015;87:649-659
25. Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med 2009;151:854-860
26. Duckworth WC, Abraira C, Moritz TE, et al.; Investigators of the VADT. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications 2011;25:355-361
27. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association [published correction appears in Diabetes Care 2009:32: 754]. Diabetes Care 2009;32:187-192
28. Kehl KG, Findeisen HM, Fardo DW, Bruemmer D, Mannino DM, SandersonWT. Race-ethnicity as an effect modifier of the association between HbAlc and mortality in U.S. adults without diagnosed diabetes. Eur J Endocrinol 2011;165: 275-281